Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network

被引:27
|
作者
Balasubramanian, SP
Murrow, S
Holt, S
Manifold, IH
Reed, MW
机构
[1] Univ Sheffield, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[2] Weston Pk Hosp, N Trent Canc Network, Sheffield S10 2SJ, S Yorkshire, England
[3] Chesterfield & N Derbyshire Gen Hosp, Chesterfield S44 5BL, England
关键词
breast cancer; guidelines; chemotherapy; radiotherapy;
D O I
10.1016/S0960-9776(02)00263-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The North Trent Cancer Network Breast Group in the United Kingdom revised its adjuvant treatment guidelines in breast cancer management in 1998. We aimed to check the compliance to the guidelines, 8 months after their introduction. Data were collected, retrospectively, from the medical records of patients with invasive breast cancer who underwent definitive surgery (in a 3-month period) in different cancer units and the cancer Centre within the North Trent Cancer Network. The overall compliance to treatment guidelines was 82% (90% and 74% for chemotherapy and radiotherapy, respectively), which was similar across the network. In 5% of cases, compliance could not be determined. On case review, 22% of the non-compliant incidents were justified and 16% seemed to be due to variation in guideline interpretation. We discuss the possible reasons for non-compliance and show a need to periodically monitor compliance to adjuvant treatment guidelines. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:136 / 141
页数:6
相关论文
共 50 条
  • [31] Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis
    Jonathan Klein
    William Tran
    Elyse Watkins
    Danny Vesprini
    Frances C. Wright
    Nicole J. Look Hong
    Sonal Ghandi
    Alex Kiss
    Gregory J. Czarnota
    BMC Cancer, 19
  • [32] Radiotherapy and combined therapy in breast cancer: Standards and innovations in the adjuvant setting
    Belkacemi, Y.
    Gligorov, J.
    Chauvet, M. -P.
    Tsoutsou, P. G.
    Boussen, H.
    Bourgier, C.
    JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION, 2010, 39 (08): : F63 - F69
  • [33] On the interaction of adjuvant radiotherapy and tamoxifen treatment for breast cancer
    Hoeller, Ulrike
    Borgmann, Kerstin
    Feyer, Petra
    Souchon, Rainer
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 (10) : 535 - 544
  • [34] Toxicity of concurrent adjuvant CMF chemotherapy and radiotherapy in patients with early breast cancer
    Yom, Cha-Kyong
    Kim, Hyun-Ah
    Moon, Byung-In
    Choe, Kuk-Jin
    Choi, Kum-Ja
    Suh, Hyun-Suk
    Choi, Hye-Young
    JOURNAL OF BREAST CANCER, 2007, 10 (02) : 147 - 152
  • [35] Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis
    Klein, Jonathan
    Tran, William
    Watkins, Elyse
    Vesprini, Danny
    Wright, Frances C.
    Hong, Nicole J. Look
    Ghandi, Sonal
    Kiss, Alex
    Czarnota, Gregory J.
    BMC CANCER, 2019, 19 (1)
  • [36] Adjuvant and neoadjuvant chemotherapy of breast cancer
    Untch, M.
    Thomssen, C.
    ONKOLOGE, 2015, 21 (03): : 231 - 238
  • [37] Adjuvant chemotherapy in primary breast cancer
    Harbeck, N
    ONKOLOGIE, 2003, 26 : 17 - 20
  • [38] Intensive adjuvant chemotherapy for breast cancer
    Robert C. F. Leonard
    Breast Cancer, 1999, 6 (4) : 386 - 390
  • [39] Adjuvant chemotherapy for primary breast cancer
    Fornier M.
    Hudis C.
    Current Oncology Reports, 2005, 7 (1) : 18 - 22
  • [40] Better compliance with hypofractionation vs. conventional fractionation in adjuvant breast cancer radiotherapy
    Rudat, Volker
    Nour, Alaa
    Hammoud, Mohamed
    Abou Ghaida, Salam
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (05) : 375 - 384